Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
A genuinely interesting research compound with, as of today, no completed human efficacy trial behind the claims made about it.
MOTS-c comes up constantly in longevity and metabolic-health discussions. It's worth being direct about where the science actually stands: early, preclinical, and not yet proven in people.
A note on regulatory status (as of July 2026): MOTS-c's Category 2 nomination was withdrawn, and the FDA removed it from that list in April 2026 — but it was not added to Category 1, and it remains in a genuine gray zone pending Pharmacy Compounding Advisory Committee review. As of mid-2026, no completed Phase 2 or Phase 3 human efficacy trial exists in the published literature.
MOTS-c is a small peptide encoded by mitochondrial DNA, discovered through genetics research into mitochondrial signaling. It's naturally produced in the body — the therapeutic version is a synthetic copy administered by injection, on the theory that supplementing it could replicate some of the metabolic effects associated with exercise.
MOTS-c is thought to activate AMPK, a cellular energy-sensing pathway also activated by exercise — which is the basis for its "exercise mimetic" reputation. This mechanism is documented in preclinical and cell-based research.
The strongest related human data comes from a different but similar compound (a MOTS-c analog developed by another company), which showed safety and some metabolic markers improving in a Phase 1 trial before that specific development program was discontinued. For MOTS-c itself, no completed large-scale human efficacy trial exists as of 2026 — claims about fat loss, exercise performance, or longevity in humans are extrapolated from mechanism and animal data, not demonstrated in controlled human studies. Notably, the World Anti-Doping Agency banned MOTS-c in 2024 specifically because of its AMPK-activating, exercise-mimetic properties — a sign it's taken seriously mechanistically, not a marker of proven human efficacy.
Without completed human trials, there's no established human safety profile. This is squarely a research-stage compound, and anyone offering it as a finished wellness therapy should be transparent about that rather than presenting it as settled science.
MOTS-c is a legitimately interesting piece of mitochondrial biology with a mechanism worth watching. It is not, today, a peptide with human trial evidence behind the claims made about it — and being upfront about that is more useful to you than pretending otherwise.
Regulatory status as of 2026-07-20.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense MOTS-c or any medication.